Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Dow Chemical to acquire Rohm and Haas

This article was originally published in Scrip

Executive Summary

Dow Chemicalhas reached a definitive agreement to acquire the speciality chemical company Rohm and Haasfor more than $15 billion, to create the world's leading speciality chemicals and advanced materials company. It will pay $78 in cash for each outstanding share, a more than 73% premium to Rohm and Haas's closing share price on July 9th. The move into more high-margin speciality chemicals should help protect Dow from the more cyclical basic chemical sales business, and it described it as a decisive move to transform Dow into an earnings growth company. Rohm and Haas is best known for its paint and electronics materials businesses but its technologies are found in a wide range of industries, including pharmaceuticals. The deal, which has been unanimously approved by the boards of both companies, remains subject to approval by Rohm and Haas shareholders and regulatory approvals.

You may also be interested in...

Urovant’s Vibegron Flops In IBS Study

Another disappointment for irritable bowel syndrome therapies as Urovant Science’s vibegron fails in a Phase II trial, likely spelling the end for the investigational indication.

Deal Watch: Bristol Teams Up With Insitro, Sensyne In AI-Directed Collaborations

Pharma pays $50m up front to tap insitro’s in vitro modeling technology, partners with Sensyne Health in blood disorders. Lilly’s COVID-19 partner AbCellera teams with Kodiak in ophthalmology R&D.

Catabasis’s Future In Doubt After DMD Phase III Failure

Another failed study in Duchenne muscular dystrophy spells the end for edasalonexent and possibly the firm.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts